How Moderna CoVid Vaccine Produces Better Protection
Scarica e ascolta ovunque
Scarica i tuoi episodi preferiti e goditi l'ascolto, ovunque tu sia! Iscriviti o accedi ora per ascoltare offline.
7 set 2021 ·
1 min. 32 sec.
Vidcast: https://youtu.be/tTmjDS-xJr4 Vaccination with the Moderna CoVid vaccine triggers more IgA anti-CoVid antibodies and anti-CoVid killer T cells compared with the Pfizer vaccine. Researchers at Harvard and MIT studied the...
mostra di più
Vidcast: https://youtu.be/tTmjDS-xJr4 Vaccination with the Moderna CoVid vaccine triggers more IgA anti-CoVid antibodies and anti-CoVid killer T cells compared with the Pfizer vaccine. Researchers at Harvard and MIT studied the immune responses of 73 vaccine recipients including 28 who received the Moderna vaccine and 45 who received the Pfizer vaccine. Analysis of the immune responses to each vaccine indicate that the Moderna vaccine produces more IgA secretory antibodies to CoVid spike, receptor binding domain, and N-terminal domain antigens. On the cell-mediated immunity front, Moderna vaccine triggers enhanced antibody dependent neutrophil phagocytosis and antibody dependent killer cell activation. Both vaccines produce similar IgG and IgM anti-CoVid antibody levels. In terms of immunity against the variants, Moderna triggers more antibodies in secretions, IgA antibodies, while Pfizer trigger more blood-borne antibodies, IgG and IgM. However, the additional IgA, RBD, and NTD antibodies triggered by Moderna in comparison to Pfizer may explain its better performance against variants including Delta. https://www.biorxiv.org/content/10.1101/2021.08.31.458247v1.full.pdf #CoVid #vaccine #Moderna #Pfizer #antibodies #cellularimmunity
mostra meno
Informazioni
Autore | Howard G. Smith MD |
Sito | - |
Tag |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company